131 completed, 70 unknown, 28 recruiting, 19 terminated. 282 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 282 | Completed 131, Unknown 70, Recruiting 28, Terminated 19, Not yet recruiting 12, Withdrawn 11, Active not recruiting 9, Enrolling by invitation 2 |
Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib) - Waldenstrom Macroglobulinaemia, Multiple Myeloma | Phase 4 | Not yet recruiting | Anne Louise Tølbøll Sørensen | 400 | 2027-03-01 | 2026-03-16 |
| Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD Gabapentin, Benzonatate 200 mg, Standard of care treatment for ILD - Interstitial Lung Disease | Phase 4 | Not yet recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 177 | 2026-10-07 | 2026-10-08 |
| Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response Pomalidomide, Rituximab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 4 | Not yet recruiting | The First Hospital of Jilin University | 27 | 2026-09-01 | 2026-08-12 |
| Clinical Efficacy of Stopping Oral Antibiotics When Symptoms Stop, Compared to 'Finishing the Course' Antibiotics for duration of symptoms, Antibiotics for duration of prescribed course - Urinary Tract Infection, Cellulitis | Phase 4 | Recruiting | Murdoch Childrens Research Institute | 200 | 2026-08-18 | 2026-08-21 |
| Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound Butterfly iQ3 ultrasound system for determination of postpartum volume status, Oral furosemide, Intravenous furosemide - Preeclampsia, Preeclampsia Postpartum | Phase 4 | Not yet recruiting | University of California, Irvine | 96 | 2026-06-15 | 2026-01-23 |
| Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy Cosibelimab, Prednisone, Sirolimus - Cutaneous Squamous Cell Carcinoma, Skin Cancer | Phase 4 | Recruiting | Dana-Farber Cancer Institute | 80 | 2026-04-23 | 2026-08-11 |
| Non Inferiority KawasakI Trial With Anakinra Anakinra, Intravenous Immunoglobulins, Human - Kawasaki Disease, Anakinra | Phase 4 | Withdrawn | Meyer Children's Hospital IRCCS | 2026-04-01 | 2026-10-26 | |
| A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Pirtobrutinib, Idelalisib - Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic | Phase 4 | Recruiting | Eli Lilly and Company | 150 | 2026-03-09 | 2026-09-22 |
| Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase Levofloxacin, Placebo - Neutropenic Fever, Acute Lymphoblastic Leukemia | Phase 4 | Terminated | Gadjah Mada University | 49 | 2026-01-01 | 2026-10-01 |
| ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial ZSDT regimen - Mantle Cell Lymphoma (MCL) | Phase 4 | Not yet recruiting | Zhengzhou University | 30 | 2025-12-31 | 2025-12-04 |
| Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma Orelabrutinib - Marginal Zone Lymphoma(MZL) | Phase 4 | Recruiting | Beijing Tongren Hospital | 88 | 2025-11-25 | 2026-01-21 |
| Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma Rituximab, Zanubrutinib - Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma | Phase 4 | Recruiting | The First Affiliated Hospital of Soochow University | 40 | 2025-11-01 | 2025-12-08 |
| Gentle Touch for Post-Mastectomy Lymphedema Gentle Touch (GT) Lymphatic Drainage (ANDOS technique), Passive Mobilization and Active-Assisted Exercises for the Upper Limb - Lymphedema, Breast Cancer | Phase 4 | Recruiting | I.R.C.C.S. Fondazione Santa Lucia | 36 | 2025-11-01 | 2025-12-02 |
| A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia Zanubrutinib - Waldenström's Macroglobulinemia | Phase 4 | Active not recruiting | BeiGene | 16 | 2025-10-17 | 2026-08-10 |
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | 90 | 2025-10-17 | 2026-01-15 |
| Intralesional Bleomycin Sclerotherapy for Low-Flow Vascular Malformations of the Head and Neck Bleomycin (Bleocel 15) - Vascular Malformations, Venous Malformation | Phase 4 | Completed | University Of Anbar | 20 | 2025-08-25 | 2026-07-27 |
| Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies Ceftazidime, Ciprofloxacin - Neutropenic Fever, Acute Lymphoblastic Leukemia | Phase 4 | Recruiting | Gadjah Mada University | 120 | 2025-06-01 | 2025-08-22 |
| Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease Rivaroxaban Oral Tablet [Xarelto], Aspirin or Clopidogrel, Warfarin - Kawasaki Disease, Coronary Artery Aneurysm | Phase 4 | Recruiting | Children's Hospital of Fudan University | 100 | 2025-06-01 | 2026-07-06 |
| Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma Glofitamab treatment - B Cell Lymphoma (BCL) | Phase 4 | Not yet recruiting | Zhengzhou University | 40 | 2025-05-30 | 2025-05-02 |
| A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma Pirtobrutinib - Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | Phase 4 | Recruiting | Eli Lilly and Company | 279 | 2025-05-20 | 2026-03-02 |
Showing 20 of 282. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (60) · Lymphoma (35) · Lymphoma, Follicular (31) · Lymphoma, Non-Hodgkin (30) · Sarcoidosis (18) · Leukemia, Lymphocytic, Chronic, B-Cell (16) · Lymphoma, Large B-Cell, Diffuse (12) · Recurrence (12) · Leukemia (11) · Lymphedema (11) · Lymphoma, B-Cell (10) · Hodgkin Disease (8) · Lymphoma, T-Cell, Cutaneous (8) · Waldenstrom Macroglobulinemia (8) · Sarcoidosis, Pulmonary (7)
Hemic and Lymphatic Diseases (282) · Immune System Diseases (242) · Lymphoproliferative Disorders (242) · Neoplasms (220) · Immunoproliferative Disorders (216) · Neoplasms by Histologic Type (216) · Lymphoma (106) · Hematologic Diseases (102) · Leukemia, Lymphoid (79) · Lymphoma, Non-Hodgkin (76) · Leukemia (75) · Pathological Conditions, Signs and Symptoms (61) · Pathologic Processes (47) · Respiratory Tract Diseases (30)
Cyclophosphamide (29) · Vincristine (24) · Dexamethasone (23) · Methotrexate (23) · Rituximab (22) · Cytarabine (21) · Mercaptopurine (16) · Doxorubicin (15) · Prednisone (15) · Asparaginase (13) · Etoposide (13) · Prednisolone (13) · Daunorubicin (12) · Granulocyte Colony-Stimulating Factor (10) · Idarubicin (8)
PETHEMA Foundation (9) · University of Cincinnati (8) · Peking University (7) · Zhengzhou University (7) · Mingzhi Zhang (6) · Ruijin Hospital (6) · Goethe University (5) · Hoffmann-La Roche (5) · Institute of Hematology & Blood Diseases Hospital, China (5) · Eisai Inc. (4) · GlaxoSmithKline (4) · Pfizer (4) · Post Graduate Institute of Medical Education and Research, Chandigarh (4) · Shandong Provincial Hospital (4) · University of Texas Southwestern Medical Center (4)
China (73) · United States (67) · Spain (25) · Germany (21) · Italy (20) · France (19) · United Kingdom (18) · Poland (13) · Russia (12) · Australia (11) · Sweden (11) · Canada (10) · Czechia (10) · South Korea (10) · India (9)
Robert P Baughman, MD (6) · Dieter Hoelzer, MD,PhD (4) · Shuhua Yi, Doc (4) · Jun Zhu (3) · Jun Zhu, MD (3) · Adolfo Martinez Tovar, PhD (2)
PMID 32632956, PMID 19144982, PMID 22442346, PMID 22493293, PMID 23024237, PMID 23770157, PMID 27561722, PMID 28751559, PMID 11863096, PMID 14585365, PMID 14752084, PMID 15014526, PMID 15158091, PMID 15225842, PMID 15257960, PMID 15770833, PMID 16648042, PMID 17223475, PMID 17410187, PMID 18165618, PMID 18240234, PMID 18263672, PMID 18626005, PMID 19167677, PMID 19219604, PMID 19564304, PMID 19951974, PMID 20118030, PMID 20560291, PMID 20660832, PMID 21575927, PMID 21828124, PMID 21890336, PMID 21932110, PMID 21940824, PMID 21987409, PMID 22198540, PMID 22405509, PMID 22677206, PMID 22966847, PMID 23275102, PMID 23317527, PMID 23383989, PMID 23574881, PMID 23590801, PMID 23615461, PMID 23753028, PMID 23775967, PMID 23775972, PMID 23938061
2009 (4), 2018 (2), 2019 (2), 2005 (1), 2016 (1), 2023 (1), P01CA128115 (1), P30CA021765 (1), R01CA078957 (1), U01CA081445 (1)